Co-Diagnostics (CODX) said Friday it has withdrawn its application to the US Food and Drug Administration for its Co-Dx PCR COVID-19 test in favor of filing an enhanced test version for clearance.
The decision followed talks with the FDA over "the ability to detect a potential deterioration of one component of the test, related to shelf-life stability," the company said.
"Co-Dx has determined that the best long-term solution would be to submit a version of the test that has been enhanced to address the matter raised in the...review process," the firm said.
The shares were rising past 5% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.